Last reviewed · How we verify
Drug: SYHA1805 tablets
Drug: SYHA1805 tablets is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Drug: SYHA1805 tablets |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: SYHA1805 tablets CI brief — competitive landscape report
- Drug: SYHA1805 tablets updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Drug: SYHA1805 tablets
What is Drug: SYHA1805 tablets?
Drug: SYHA1805 tablets is a Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Who makes Drug: SYHA1805 tablets?
Drug: SYHA1805 tablets is developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (see full CSPC ZhongQi Pharmaceutical Technology Co., Ltd. pipeline at /company/cspc-zhongqi-pharmaceutical-technology-co-ltd).
What development phase is Drug: SYHA1805 tablets in?
Drug: SYHA1805 tablets is in Phase 1.